Please ensure Javascript is enabled for purposes of website accessibility

Are These 3 Biotechs Destined to Be Bought Out?

By George Budwell - Apr 24, 2016 at 2:59PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Are Celator Pharmaceuticals, Geron Corp., and Juno Therapeutics barreling toward a buyout?

The merger and acquisition frenzy that's been spreading across the biotech landscape over the last few years might be about to hit fever pitch. After all, heavyweights like Allergan, Gilead Sciences (GILD 0.91%), Celgene Corp. (CELG)Johnson & Johnson (JNJ 0.06%), and Pfizer have all signaled their intent to create value for shareholders through either bolt-on acquisitions or mergers with similarly sized peers.

Image source: Pixabay.

Perhaps stoking these M&A flames even further is the fact that biotech is presently a target-rich space, with valuations becoming more reasonable and several clinical-stage drugmakers reporting strong top-line data for their lead product candidates of late. In short, there is a clear demand for M&A among the top dogs in biopharma, and the supply of actionable buyout targets seems more than ample. 

While there are probably over a dozen compelling buyout candidates floating around the industry right now, I personally think the clinical-stage cancer companies Celator Pharmaceuticals (NASDAQ: CPXX), Geron Corp. (GERN -3.55%), and Juno Therapeutics (JUNO) are the cream of the crop. Here's why. 

Celator is set to transform the standard of care for AML
Celator shocked many onlookers last month after its lead drug candidate, Vyxeos, hit the mark in a pivotal stage trial for secondary acute myeloid leukemia, AML, causing its shares to more than quadruple in value. This stock wasn't even on the radar of most analysts prior to Vyxeos' breakthrough a few short weeks ago, and only now is anyone attempting to value the tiny drugmaker.

With little to go on besides the broad-strokes estimate that the entire AML market is expected to rise to around $900 million in sales by 2020, Celator still looks woefully undervalued with a potential new standard of care in tow and a market cap of less than $600 million at present. And such an intriguing value proposition could certainly drive interest from big pharma or big biotech from an acquisition standpoint. After all, novel cancer drugs are highly prized among major drugmakers because they can command premium pricing structures, and they frequently enjoy low levels of competition because of the sheer difficulty of developing rival therapies.

Image source: Pixabay.

Given that Vyxeos is indicated for a rare blood disorder with little to no competition at the moment and there have been no major advancements in the treatment of AML in the last three decades, I think this drug would make an excellent addition to either Celgene or Gilead's oncology portfolios and would dovetail nicely with their overarching focus on hematological malignancies. So, my gut feeling is that Celator will end up fetching a tender offer before Vyxeos' regulatory application is submitted to the FDA later this year -- with Celgene and Gilead being the two most likely suitors. 

Geron's novel telomerase inhibitor is a blockbuster-in-waiting
As I've discussed before, Geron is a small-cap biotech that seems to be structured at this stage to be eventually folded into J&J, the company's development partner for imetelstat. The long and short of it is that Geron has put all of its eggs into the imetelstat basket, hoping this novel telomerase inhibitor can prove to be a game-changer for a variety of hard-to-treat blood disorders like myelofibrosis and myelodysplastic syndrome. Most importantly, Geron has essentially handed over the bulk of clinical responsibilities to J&J's biotech subsidiary Janssen, and even slashed its workforce to a grand total of 19 employees to boot. 

However, the main reason Geron seems destined, to me, to become part of J&J -- if most of imetelstat's ongoing clinical trials go as planned -- lies in J&J's recent past. Not long ago, J&J reportedly lost out on acquiring the remaining rights to blood cancer drug Imbruvica -- a drug it identified early on as a potential blockbuster, yet failed to acquire in whole in a timely manner. If imetelstat appears likely to live up to J&J's own estimates as a blockbuster-in-waiting, I doubt the drugmaker is going to make the same mistake twice. Rather, I expect J&J will decide to sally forth with a tender offer -- or not -- soon after imetelstat's wraps up its current bevy of clinical trials, thereby avoiding a bidding war that could drive Geron's price up to unreasonable levels.  

Juno is basically engaged to Celgene at this point
Last year, Juno and Celgene announced a 10-year deal to develop adoptive T cell therapies for patients afflicted with cancer or autoimmune diseases. Per the terms of this massive deal, Celene bought approximately 9.1 million shares of Juno stock and some rights to its pipeline, with an option to buy up to a 30% stake in the biotech going forward. If this $1 billion-plus upfront investment wasn't enough, Celgene even agreed to certain lock-up provisions on its share ownership. Earlier this month, Celgene deepened this relationship by opting in on Juno's CD19 CAR-T program indicated for a host blood cancers, handing over a $50 million payment to do so. 

From an outsider's view, this hefty investment in Juno seems to boil down to Celgene wanting to protect its dominant position in the high-growth hematology market. While CAR-Ts still have a ways to go to prove they can overcome serious safety issues such as cytokine release syndrome, the early clinical results have indicated that these types of treatments could revolutionize the standard of care for several fatal blood disorders, perhaps displacing chemotherapy-based treatments altogether. By locking up a nice chunk of Juno early on, Celgene is securing itself a seat at the CAR-T table, if this novel cohort of immunotherapies does indeed hit pay dirt. 

What's next?
Buying any stock on the hope that a company will be bought out is never a good idea. Mergers and acquisitions, after all, tend to come out of left field and never seem to follow the path of least resistance. That's why investors need to consider the underlying business prospects of these -- or any other -- buyout candidates as stand-alone entities before jumping in headfirst.

Of these three biotechs in particular, I think Celator is a great pick-up regardless of whether a big biotech comes calling thanks to Vyxeos' value proposition. On the flip side, Geron and Juno are highly unlikely to even remain independent entities if their clinical pipelines perform as expected, as a result of their tight relationships with J&J and Celgene, respectively. So, I think it's buyout or bust for both Geron and Juno, which is an issue investors should probably factor into their buying or selling decisions moving forward. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Geron Corporation Stock Quote
Geron Corporation
$1.36 (-3.55%) $0.05
Juno Therapeutics, Inc. Stock Quote
Juno Therapeutics, Inc.
Johnson & Johnson Stock Quote
Johnson & Johnson
$178.18 (0.06%) $0.10
Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
$62.80 (0.91%) $0.56
Celgene Corporation Stock Quote
Celgene Corporation

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/17/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.